Personalis, Inc. (PSNL) stock
PSNLNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 5/30379% above fair value
$15.71−0.15 (-0.95%)
Close on Nov 13, 2026Market cap $1.68BP/E –Yield –
Earnings
Personalis's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Feb 25, 2027
Q4 FY2026 · estimated, after the close
Revenue, Q3 FY2026
$25.60M
+76.6% on a year earlier
EPS, Q3 FY2026
-$0.32
-$0.24 a year earlier
Latest guidance
Raised
May 7, 2026 · 8 items
Quarterly results
Revenue and earnings per share from each of Personalis's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 25, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 4, 2026after the close | $25.60M | +76.6% | -$0.32 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 4, 2026after the close | $22.40M | +30.2% | -$0.30 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 7, 2026after the close | $15.50M | -24.8% | -$0.29 | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 26, 2026after the close | $17.30M | +3.0% | -$0.26 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 4, 2025after the close | $14.50M | -43.6% | -$0.24 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 5, 2025after the close | $17.20M | -23.9% | -$0.23 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 6, 2025after the close | $20.60M | +5.6% | -$0.18 | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 27, 2025after the close | $16.80M | -14.7% | -$0.23 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 6, 2024after the close | $25.70M | +41.2% | – | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 7, 2024after the close | $22.60M | +35.3% | -$0.24 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 8, 2024after the close | $19.50M | +3.2% | -$0.26 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 28, 2024after the close | $19.70M | +18.0% | -$0.54 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 7, 2023after the close | $18.20M | +22.1% | -$0.60 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 8, 2023after the close | $16.70M | -8.2% | -$0.50 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 3, 2023after the close | $18.90M | +24.3% | -$0.61 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 23, 2023after the close | $16.70M | -19.3% | -$0.67 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 2, 2022after the close | $14.90M | -33.2% | -$0.58 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 3, 2022after the close | $18.20M | – | -$0.60 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 4, 2022after the close | $15.20M | – | -$0.63 | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 24, 2022after the close | $20.70M | – | -$0.45 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 4, 2021before the open | $22.30M | – | -$0.40 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 4, 2021after the close | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 5, 2021after the close | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Jan 27, 2021before the open | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 5, 2020after the close | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Personalis's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| Total company revenue | FY2026 | $78.00M – $80.00M | – | New | May 7, 2026 |
| Total company revenue | FY2026 | $78.00M – $80.00M | – | New | Feb 26, 2026 |
| Gross margin | FY2026 | 15% – 20% | – | New | May 7, 2026 |
| Gross margin | FY2026 | 15% – 20% | – | New | Feb 26, 2026 |
| Cash usage | FY2026 | $100.00M | – | Raised | May 7, 2026 |
| Cash usage | FY2026 | $100.00M | – | Lowered | Feb 26, 2026 |
| Clinical revenue | FY2026 | $10.00M – $11.00M | – | New | Feb 26, 2026 |
| Clinical test volume | FY2026 | 43,000 – 45,000 | – | New | May 7, 2026 |
| clinical volume | FY2026 | 43,000 – 45,000 | – | New | Feb 26, 2026 |
| Net loss | FY2026 | -$105.00M | – | New | May 7, 2026 |
| Net loss | FY2026 | $105.00M | – | Raised | Feb 26, 2026 |
| Revenue from pharma testing services and all other customers | FY2026 | $55.00M – $56.00M | – | Raised | Feb 26, 2026 |
| Revenue from population sequencing and enterprise sales | FY2026 | $13.00M | – | Lowered | Feb 26, 2026 |
Guidance vs results
The last range Personalis gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| FY2025 | Revenue | $68.00M – $73.00M | $69.60MΣ4Q | Within range |
| Q4 FY2025 | Revenue | $15.70M – $20.70M | $17.30M | Within range |
| Q3 FY2025 | Revenue | $12.00M – $14.00M | $14.50M | Above range |
| Q2 FY2025 | Revenue | $19.50M – $20.50M | $17.20M | Below range |
| Q1 FY2025 | Revenue | $17.00M – $18.00M | $20.60M | Above range |
| Q4 FY2024 | Revenue | $15.00M – $16.00M | $16.80M | Above range |
| Q3 FY2024 | Revenue | $21.00M – $22.00M | $25.70M | Above range |
| Q2 FY2024 | Revenue | $19.50M – $20.50M | $22.60M | Above range |
| Q1 FY2024 | Revenue | $18.00M – $19.00M | $19.50M | Above range |
| Q4 FY2023 | Revenue | $19.00M – $20.00M | $19.70M | Within range |
| Q3 FY2023 | Revenue | $17.00M | $18.20M | Above range |
| Q2 FY2023 | Revenue | $16.00M – $17.00M | $16.70M | Within range |
| Q1 FY2023 | Revenue | $17.50M | $18.90M | Above range |
| Q4 FY2021 | Revenue | $20.20M – $20.40M | $20.70M | Above range |
Guidance history
Every forecast Personalis put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| May 7, 2026 | Gross margin | FY2026 | 15% – 20% | New |
| May 7, 2026 | Net loss | FY2026 | -$105.00M | New |
| May 7, 2026 | Clinical test volume | FY2026 | 43,000 – 45,000 | New |
| May 7, 2026 | Cash usage | FY2026 | $100.00M | Raised |
| May 7, 2026 | Total company revenue | FY2026 | $78.00M – $80.00M | New |
| May 7, 2026 | Clinical revenue | FY2026 | $10.00M – $11.00M | Lowered |
| May 7, 2026 | Revenue from pharma testing services and all other customers | FY2026 | $55.00M – $56.00M | Raised |
| May 7, 2026 | Revenue from population sequencing and enterprise sales | FY2026 | $13.00M | Lowered |
| Feb 26, 2026 | Gross margin | FY2026 | 15% – 20% | New |
| Feb 26, 2026 | clinical volume | FY2026 | 43,000 – 45,000 | New |
| Feb 26, 2026 | Clinical revenue | FY2026 | $10.00M – $11.00M | New |
| Feb 26, 2026 | Revenue from pharma testing services and all other customers | FY2026 | $55.00M – $56.00M | Raised |
| Feb 26, 2026 | Revenue from population sequencing and enterprise sales | FY2026 | $13.00M | Lowered |
| Feb 26, 2026 | Net loss | FY2026 | $105.00M | Raised |
| Feb 26, 2026 | Cash usage | FY2026 | $100.00M | Lowered |
| Feb 26, 2026 | Total company revenue | FY2026 | $78.00M – $80.00M | New |
| Nov 4, 2025 | Gross margin | FY2025 | 22% – 24% | New |
| Nov 4, 2025 | Cash usage | FY2025 | $75.00M | Raised |
| Nov 4, 2025 | Net loss | FY2025 | -$85.00M | New |
| Nov 4, 2025 | Total company revenue | FY2025 | $68.00M – $73.00M | New |
| Nov 4, 2025 | Revenue from pharma tests and services, and all other customers | FY2025 | $50.00M – $54.00M | Lowered |
| Nov 4, 2025 | Revenue from population sequencing and enterprise sales | FY2025 | $16.50M – $17.00M | Lowered |
| Nov 4, 2025 | Revenue from clinical tests reimbursed | FY2025 | $1.50M – $2.00M | Lowered |
| Nov 4, 2025 | Total company revenue | Q4 FY2025 | $15.70M – $20.70M | New |
| Nov 4, 2025 | Revenue from pharma tests and services, and all other customers | Q4 FY2025 | $12.00M – $17.00M | Lowered |
| Nov 4, 2025 | Revenue from population sequencing and enterprise sales | Q4 FY2025 | $3.70M | Lowered |
| Aug 5, 2025 | Gross margin | FY2025 | 22% – 24% | Reaffirmed |
| Aug 5, 2025 | Revenue from pharma tests and services, and all other customers | Q3 FY2025 | $11.00M – $13.00M | New |
| Aug 5, 2025 | Revenue from population sequencing and enterprise sales | Q3 FY2025 | $1.00M | Lowered |
| Aug 5, 2025 | Revenue from pharma tests and services, and all other customers | FY2025 | $52.00M – $58.00M | Lowered |
| Aug 5, 2025 | Revenue from population sequencing and enterprise sales | FY2025 | $15.00M – $16.00M | Lowered |
| Aug 5, 2025 | Revenue from clinical tests reimbursed | FY2025 | $3.00M – $6.00M | Lowered |
| Aug 5, 2025 | Net loss | FY2025 | -$85.00M | Lowered |
| Aug 5, 2025 | Cash usage | FY2025 | $75.00M | Raised |
| Aug 5, 2025 | Total company revenue | Q3 FY2025 | $12.00M – $14.00M | New |
| Aug 5, 2025 | Total company revenue | FY2025 | $70.00M – $80.00M | Raised |
| May 6, 2025 | Gross margin | FY2025 | 22% – 24% | Raised |
| May 6, 2025 | Net loss | FY2025 | -$83.00M | New |
| May 6, 2025 | Cash usage | FY2025 | $75.00M | Raised |
| May 6, 2025 | Total company revenue | Q2 FY2025 | $19.50M – $20.50M | New |
| May 6, 2025 | Revenue from pharma tests and services, and all other customers | Q2 FY2025 | $13.00M – $14.00M | Lowered |
| May 6, 2025 | Revenue from population sequencing and enterprise sales | Q2 FY2025 | $6.50M | Lowered |
| May 6, 2025 | Total company revenue | FY2025 | $80.00M – $90.00M | Reaffirmed |
| May 6, 2025 | Revenue from pharma tests and services, and all other customers | FY2025 | $62.00M – $64.00M | Lowered |
| May 6, 2025 | Revenue from population sequencing and enterprise sales | FY2025 | $15.00M – $16.00M | Lowered |
| May 6, 2025 | Revenue from clinical tests reimbursed | FY2025 | $3.00M – $10.00M | Lowered |
| Feb 27, 2025 | Gross margin | FY2025 | 21% – 23% | New |
| Feb 27, 2025 | Total company revenue | Q1 FY2025 | $17.00M – $18.00M | New |
| Feb 27, 2025 | Total company revenue | FY2025 | $80.00M – $90.00M | New |
| Nov 6, 2024 | Net loss | FY2024 | -$85.00M | Lowered |
| Nov 6, 2024 | Cash usage | FY2024 | $53.00M – $55.00M | Raised |
| Nov 6, 2024 | Total company revenue | Q4 FY2024 | $15.00M – $16.00M | New |
| Nov 6, 2024 | Revenue from pharma tests, enterprise sales, and other customers | Q4 FY2024 | $15.00M – $16.00M | Reaffirmed |
| Nov 6, 2024 | Total company revenue | FY2024 | $83.00M – $84.00M | Raised |
| Nov 6, 2024 | Revenue from pharma tests, enterprise sales, and all other customers | FY2024 | $76.00M – $77.00M | Lowered |
| Nov 6, 2024 | Revenue from population sequencing | FY2024 | $7.00M | Lowered |
| Aug 7, 2024 | Cash usage | FY2024 | $60.00M | Lowered |
| Aug 7, 2024 | Non-GAAP net loss | FY2024 | $75.00M | Lowered |
| Aug 7, 2024 | Total company revenue | Q3 FY2024 | $21.00M – $22.00M | New |
| Aug 7, 2024 | Total company revenue | FY2024 | $79.00M – $81.00M | Raised |
| May 8, 2024 | Cash usage | FY2024 | $62.00M | Reaffirmed |
| May 8, 2024 | Non-GAAP net loss | FY2024 | $77.00M | New |
| May 8, 2024 | Total company revenue | Q2 FY2024 | $19.50M – $20.50M | New |
| May 8, 2024 | Total company revenue | FY2024 | $76.00M – $78.00M | Raised |
| Feb 28, 2024 | Net loss | FY2024 | $80.00M | New |
| Feb 28, 2024 | Cash usage | FY2024 | $62.00M | Lowered |
| Feb 28, 2024 | Total company revenue | Q1 FY2024 | $18.00M – $19.00M | New |
| Feb 28, 2024 | Revenue from pharma tests, enterprise sales, and other customers | Q1 FY2024 | $16.00M – $17.00M | Lowered |
| Feb 28, 2024 | Revenue from population sequencing | Q1 FY2024 | $2.00M | Lowered |
| Feb 28, 2024 | Total company revenue | FY2024 | $73.00M – $75.00M | New |
| Feb 28, 2024 | Revenue from pharma tests, enterprise sales, and all other customers | FY2024 | $65.00M – $67.00M | Lowered |
| Feb 28, 2024 | Revenue from population sequencing | FY2024 | $8.00M | Lowered |
| Nov 7, 2023 | Net loss | FY2023 | $103.00M | Raised |
| Nov 7, 2023 | Total company revenue | Q4 FY2023 | $19.00M – $20.00M | New |
| Nov 7, 2023 | Total company revenue | FY2023 | $73.00M – $74.00M | Raised |
| Aug 8, 2023 | Net loss | FY2023 | $103.00M | Raised |
| Aug 8, 2023 | Cash usage | FY2023 | $70.00M | Lowered |
| Aug 8, 2023 | Total company revenue | Q3 FY2023 | $17.00M | New |
| Aug 8, 2023 | Total company revenue | FY2023 | $70.00M – $72.00M | Raised |
| May 3, 2023 | Net loss | FY2023 | $103.00M | Raised |
| May 3, 2023 | Cash usage | FY2023 | $75.00M | Lowered |
| May 3, 2023 | Total company revenue | Q2 FY2023 | $16.00M – $17.00M | New |
| May 3, 2023 | Revenue from pharma tests, enterprise sales, and other customers | Q2 FY2023 | $13.00M – $14.00M | Lowered |
| May 3, 2023 | Revenue from population sequencing | Q2 FY2023 | $3.00M | Lowered |
| May 3, 2023 | Total company revenue | FY2023 | $68.00M – $72.00M | Raised |
| May 3, 2023 | Revenue from pharma tests, enterprise sales, and all other customers | FY2023 | $59.00M – $63.00M | Lowered |
| May 3, 2023 | Revenue from population sequencing | FY2023 | $9.00M | Lowered |
| Feb 23, 2023 | Cash usage | FY2023 | $75.00M | Lowered |
| Feb 23, 2023 | Net loss | FY2023 | $103.00M | New |
| Feb 23, 2023 | Total company revenue | Q1 FY2023 | $17.50M | New |
| Feb 23, 2023 | Revenue from pharma tests, enterprise sales, and other customers | Q1 FY2023 | $14.50M | Lowered |
| Feb 23, 2023 | Revenue from population sequencing | Q1 FY2023 | $3.00M | Lowered |
| Feb 23, 2023 | Total company revenue | FY2023 | $68.00M – $72.00M | New |
| Feb 23, 2023 | Revenue from pharma tests, enterprise sales, and all other customers | FY2023 | $59.00M – $63.00M | Lowered |
| Feb 23, 2023 | Revenue from population sequencing | FY2023 | $9.00M | Lowered |
| Nov 2, 2022 | Net loss | FY2022 | $111.00M – $114.00M | Narrowed |
| Nov 2, 2022 | Total company revenue | FY2022 | $63.00M – $64.00M | Narrowed |
| Aug 3, 2022 | Revenue from biopharma and all other customers, excluding the VA MVP | FY2022 | $55.00M – $60.00M | Lowered |
| Aug 3, 2022 | Net loss | FY2022 | $110.00M – $115.00M | Raised |
| Aug 3, 2022 | Total company revenue | FY2022 | $62.00M – $67.00M | Reaffirmed |
| May 4, 2022 | Net loss | FY2022 | $110.00M – $115.00M | Reaffirmed |
| May 4, 2022 | Total company revenue | FY2022 | $62.00M – $67.00M | Lowered |
| Feb 24, 2022 | Net loss | FY2022 | $110.00M – $115.00M | New |
| Feb 24, 2022 | Total company revenue | FY2022 | $67.00M | New |
| Nov 4, 2021 | Net Loss | Q4 FY2021 | $22.00M – $23.00M | New |
| Nov 4, 2021 | Net Loss | FY2021 | $67.00M – $68.00M | New |
| Nov 4, 2021 | Total revenue | Q4 FY2021 | $20.20M – $20.40M | New |
| Nov 4, 2021 | Total revenue | FY2021 | $85.00M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Personalis filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Update
- Results
- Results
See a number that looks wrong?